Pulmonary hypertension is abnormally high blood pressure in the arteries supplying the lungs, which forces the right side of the heart to work harder until it eventually fails. It has several distinct causes — some treatable, some not — and treatment has improved enormously over the past two decades.
What's actually going on in research
Sotatercept, an activin receptor ligand trap, has become the first drug to target the imbalance between cell growth and anti-growth signals in the pulmonary arteries, and it improves exercise capacity and outcomes on top of existing therapies. Combination approaches using endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin pathway drugs are now standard, and trials are testing new combinations and sequences. Gene therapy and cell therapy approaches targeting the underlying vascular biology are in early human trials.
Sotatercept
This first-in-class drug balances the growth signals that thicken pulmonary artery walls. Added to background therapy in trials, it improved walking distance and reduced the risk of clinical deterioration.
Upfront combination therapy
Starting with two or three pulmonary hypertension drugs simultaneously rather than sequentially is being tested to see if more aggressive early treatment prevents right heart failure.
Gene and cell therapy
Early trials are delivering genes or engineered cells to pulmonary artery walls to reverse the vascular remodeling that drives pressure elevation in heritable and idiopathic subtypes.
What to know before you search
Eligibility depends on pulmonary hypertension group and subtype, hemodynamics (mean PAP, PVR), 6-minute walk distance, background therapy, and WHO functional class.
What types of trials are currently open
- Drug trials — Testing new pulmonary vasodilators or combination strategies in pulmonary arterial hypertension.
- Right heart failure trials — Testing treatments for right ventricular failure complicating pulmonary hypertension.
- Group 2 and 3 trials — Testing approved and new drugs in pulmonary hypertension caused by left heart disease or lung disease.
- Surgical and intervention trials — Evaluating balloon pulmonary angioplasty and pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
- Observational studies — Tracking disease progression, outcomes, and long-term treatment responses across pulmonary hypertension groups.
Recently added Pulmonary Hypertension trials
Share medical records from your cancer treatment
This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors. 90 eligible patients will be assigned to: Cohort 1: GP (gemcitabine/cisplatin) + adebrelimab Cohort 2: Apatinib + adebrelimab Cohort 3: S-1 (tegafur/gimeracil/oteracil) + adebrelimab Outcomes will be compared against historical real-world controls receiving standard chemotherapy.
Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge. In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.
Find Pulmonary Hypertension trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.